COMPARISON OF THE EFFECTS OF E3810 AND OMEPRAZOLE ON DIAZEPAM PHARMACOKINETICS IN EXTENSIVE AND POOR METABOLIZERS OF S-MEPHENYTOIN

被引：0
|
作者：
ISHIZAKI, T
CHIBA, K
MANABE, K
KOYAMA, E
YASUDA, S
HORAI, Y
TOMONO, Y
YAMATO, S
机构：
[1] NTL MED CTR,CLIN RES INST,DIV CLIN PHARMACOL,TOKYO,TOKYO,JAPAN
[2] EISAI & CO LTD,TOKYO,TOKYO,JAPAN
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1994年 / 55卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：141 / 141
页数：1
相关论文
共 28 条
  • [21] Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam
    Otani, K
    Yasui, N
    Kaneko, S
    Ohkubo, T
    Osanai, T
    Sugawara, K
    Hayashi, K
    Chiba, K
    Ishizaki, T
    NEUROPSYCHOPHARMACOLOGY, 1997, 16 (01) : 8 - 14
  • [22] Evaluation of the Effects of 20 Nonsynonymous Single Nucleotide Polymorphisms of CYP2C19 on S-Mephenytoin 4′-Hydroxylation and Omeprazole 5′-Hydroxylation
    Wang, Huijuan
    An, Nianzhen
    Wang, Hao
    Gao, Yiwen
    Liu, Duan
    Bian, Ting
    Zhu, Juanli
    Chen, Chao
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (05) : 830 - 837
  • [23] The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6
    Tammara, B
    Trang, JM
    Miyamoto, G
    Kitani, M
    Brisson, J
    Bramer, SL
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (05): : 492 - 500
  • [24] AN EXPLORATORY COMPARISON OF THE SINGLE DOSE PHARMACOKINETICS OF THE β3-ADRENOCEPTOR AGONIST MIRABEGRON IN HEALTHY CYP2D6 POOR AND EXTENSIVE METABOLIZERS
    van Gelderen, E. M.
    Li, Q.
    Meijer, J.
    Schaddelee, M. P.
    Takusagawa, S.
    Sugawara, T.
    de Koning, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S88 - S88
  • [25] Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
    Chang, M
    Dahl, ML
    Tybring, G
    Gotharson, E
    Bertilsson, L
    PHARMACOGENETICS, 1995, 5 (06): : 358 - 363
  • [26] Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P4502C19)
    Sandwall, P
    Lo, MW
    Jonzon, B
    Dalén, P
    Furtek, C
    Ritter, M
    Alván, G
    McCrea, J
    Sjoqvist, F
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (04) : 279 - 283
  • [27] INTERSTRAIN COMPARISON OF HEPATIC AND RENAL MICROSOMAL CARCINOGEN METABOLISM AND LIVER S9-MEDIATED MUTAGENICITY IN DA AND LEWIS RATS PHENOTYPED AS POOR AND EXTENSIVE METABOLIZERS OF DEBRISOQUINE
    HIETANEN, E
    MALAVEILLE, C
    CAMUS, AM
    BEREZIAT, JC
    BRUN, G
    CASTEGNARO, M
    MICHELON, J
    IDLE, JR
    BARTSCH, H
    DRUG METABOLISM AND DISPOSITION, 1986, 14 (01) : 118 - 126
  • [28] Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19)
    P. Sandwall
    M.-W. Lo
    B. Jonzon
    P. Dalén
    C. Furtek
    M. Ritter
    G. Alván
    J. McCrea
    F. Sjöqvist
    European Journal of Clinical Pharmacology, 1999, 55 : 279 - 283
123